FDA Accepts Supplement for IMFINZI (Durvalumab) by AstraZeneca
The FDA has accepted a supplemental application for IMFINZI (Durvalumab) from AstraZeneca.
Asset / Drug
Drug and asset intelligence for IMFINZI with 13 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
June 17, 2026 · N/A